You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Pfizer scores a speedy review in the US for Duchenne gene therapy

Pfizer’s investigational gene therapy for Duchenne muscular dystrophy (DMD) has been granted a fast track designation from the US Food and Drug Administration (FDA).